Minocycline may help treat brain inflammation and cognitive issues in sickle cell disease.
Minocycline as a potential therapy for neuroinflammation and cognitive deficit in sickle cell disease
['FUNDING_R01'] · UNIVERSITY OF CINCINNATI · NIH-11227480
This study is looking at how inflammation in the brain affects thinking and behavior in people with sickle cell disease, and it will explore whether a medication called minocycline can help improve brain health and overall quality of life for those patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CINCINNATI (nih funded) |
| Locations | 1 site (CINCINNATI, UNITED STATES) |
| Trial ID | NIH-11227480 on ClinicalTrials.gov |
What this research studies
This research investigates how neuroinflammation contributes to cognitive and behavioral deficits in patients with sickle cell disease (SCD). The study aims to understand the relationship between neuroinflammation and cognitive decline, focusing on the role of small molecules like minocycline as potential treatments. By examining the effects of these treatments on brain health and cognitive function, the research seeks to identify effective strategies for improving the quality of life for SCD patients. Participants may undergo assessments to evaluate cognitive function and receive potential therapeutic interventions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with sickle cell disease who experience cognitive or behavioral deficits.
Not a fit: Patients without sickle cell disease or those who do not exhibit cognitive or behavioral issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve cognitive function and overall quality of life for patients with sickle cell disease.
How similar studies have performed: Previous research has shown promising results in using similar approaches to address cognitive deficits related to neuroinflammation, indicating potential for success in this area.
Where this research is happening
CINCINNATI, UNITED STATES
- UNIVERSITY OF CINCINNATI — CINCINNATI, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HYACINTH, HYACINTH IDU — UNIVERSITY OF CINCINNATI
- Study coordinator: HYACINTH, HYACINTH IDU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.